SAIL66, a next generation CLDN6-targeting T-cell engager, demonstrates potent antitumor efficacy through dual binding to CD3/CD137

SAIL66, a next generation CLDN6-targeting T-cell engager, demonstrates potent antitumor efficacy through dual binding to CD3/CD137

Background Ovarian cancer remains a formidable challenge in oncology, necessitating innovative therapeutic approaches. Claudin-6 (CLDN6), a member of the tight junction molecule CLDN family, exhibits negligible expression in healthy tissues but displays aberrant upregulation in various malignancies,...

Full description

Saved in:
Bibliographic Details
Main Authors: Shu Feng, Hiroyuki Aburatani, Mika Kamata-Sakurai, Shinya Ishii, Takayuki Kamikawa, Naoki Kimura, Masaru Muraoka, Kenji Taniguchi, Ryo Uchikawa, Moe Yoshimoto, Sho Akai, Tatsushi Kodama, Mei Shimada, Takehisa Kitazawa, Tomoyuki Igawa, Momoko Miura-Okuda, Chie Kato, Junko Shinozuka, Sotaro Naoi, Nanami Tomioka, Nishiki Nagaya, Chai Ling Pang, Gupta Garvita
Format: Article
Language:English
Published: BMJ Publishing Group 2024-10-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/12/10/e009563.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/12/10/e009563.full

Similar Items